Very high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-known prevalent role of obesity in MS pathogenesis. Because of various reasons, many medications haven’t achieved wide acceptance in clinical settings. The article summarizes the experience in BM reduction with an effective drug – orlistat (Xenical®). Based on the authentic authors’ data, beneficial effects of orlistat on carbohydrate and lipid metabolism, 24-hour blood pressure profile, and cerebral perfusion are demonstrated. The authors prove that orlistat is highly recommended for cardiovascular complication risk reduction in MS patients
